The Times Australia
Fisher and Paykel Appliances
The Times World News

.

Opioids ease osteoarthritis pain only slightly. Their deadly risks need to be weighed against any benefit

  • Written by Wasim Awal, Doctor of Medicine, Griffith University
Opioids ease osteoarthritis pain only slightly. Their deadly risks need to be weighed against any benefit

Osteoarthritis is one of the leading causes of disability, affecting more than 500 million people globally[1].

Most doctors encourage physical activity, maintaining a healthy weight and short-term use of a simple painkiller like paracetamol to manage the pain.

Opioids, like codeine, morphine or oxycodone, have a reputation as powerful painkillers and are commonly prescribed for persistent osteoarthritis pain. Up to 40% of people with knee osteoarthritis in the US are treated with opioid medicines[2].

People who begin taking opioid medicines to treat chronic pain conditions like osteoarthritis may end up taking them on an ongoing basis and expose themselves to serious harms including dependence, overdose and even death[3].

In Australia, deaths from opioids now exceed the national road toll[4].

In our new study, published today[5], we reviewed all the relevant research and found opioids only offer very small benefits for the relief of osteoarthritis pain. Patients – and their doctors – need to carefully weigh up the risks and benefits of taking these commonly prescribed medicines for the treatment of osteoarthritis.

Read more: 1 in 5 Aussies over 45 live with chronic pain, but there are ways to ease the suffering[6]

Small shifts on the pain scale

Opioids are types of narcotic drugs that work on the central nervous system to relieve pain. Our team from the University of Sydney and Sydney Musculoskeletal Health[7] conducted a large review of 36 randomised controlled trials that compared opioid medicines to a placebo (or inactive pill) for osteoarthritis pain of the knee or hip. This kind of review represents the highest level of research evidence.

The combined trial results show the overall effects of opioid medicines compared to placebo on important outcomes such as pain and function.

The review found opioid medicines provide a very small improvement in pain and function compared with placebo. This improvement amounted to approximately 5 points or less on a 0 (no pain) to 100 (worst pain imaginable) pain scale. These modest effects are similar to what is expected if using paracetamol for osteoarthritis[8] and less than one-third as effective as certain non-steroidal anti-inflammatory pills or creams[9] including ibuprofen.

Our findings add weight to other research into the effectiveness of opioids. Australian researchers observed[10] late last year that opioids were no more effective than mild painkillers after surgery for fracture.

man holds sore knee
Patients may get just as much pain relief from paracetamol or ibuprofen. Shutterstock[11]

Read more: Opioid script changes mean well, but have left some people in chronic pain[12]

More was not more effective

Importantly, we found no significant link between the dosage amount of opioid medicine and the level of pain relief. So, if an opioid medicine isn’t helping manage pain, increasing the dose is not likely to provide any further benefit.

The harms of opioids are well known, particularly at higher doses. Common side effects include nausea, constipation and fatigue. The review[13] revealed the risk of experiencing unwanted effects like these when taking an opioid is almost 1.5 times greater than when taking a placebo.

Opioids also carry a risk of tolerance[14], which happens when the current dose is no longer helpful in managing the pain and a larger dose is needed to achieve the same effect.

These medicines can also lead to dependence[15], where stopping the opioid suddenly can lead to unpleasant withdrawal symptoms such as an inability to sleep, agitation, sweating and heart palpitations.

The risk of life-threatening overdose events is high with regular use of opioid medicines, as opioids inhibit the part of the brain that regulates our breathing. Opioids are the most common cause of drug-induced deaths in Australia[16], with 1,121 deaths reported in 2019 alone. The majority of these deaths (around 56%) resulted from prescription opioid medicines rather than illicit opioids such as heroin.

Scientists are working on new pain-relieving compounds[17] that activate opioids receptors but are safer for patients.

Read more: Designing less addictive opioids, through chemistry[18]

Patients get hooked and fast

In the past few years, growing evidence has revealed taking opioid medicines for just a short amount of time can lead to persistent use.

About 24% of patients who use opioid medicines for 12 days will continue to use opioids for at least a year[19]. This goes up to 43% after just one month of opioid use.

With long-term use, the risk of adverse effects is greatly increased, especially as it is likely people will need higher doses to achieve the same level of pain control.

Chronic pain conditions like osteoarthritis are also commonly treated with long-acting formulations of opioid medicines such as OxyContin. However these types of opioids, which are intended to be taken regularly instead of only when needed, are associated with a six-fold increased risk of overdose[20] compared with short-acting formulations.

Choose wisely

Our new findings will provide people with realistic expectations about the benefits these drugs can provide for chronic pain. Then they can carefully weigh this up with the risks.

Opioid medicines provide modest benefits for osteoarthritis which is similar to, or considerably less than, more simple analgesics like paracetamol or ibuprofen.

If you do choose or are prescribed to start an opioid medicine, discuss the benefits and potential harms with a doctor first. If you are concerned about the amount of opioid medicines you are using, or the duration you have been using them, speak with your doctor about a dose-reduction plan[21].

Read more https://theconversation.com/opioids-ease-osteoarthritis-pain-only-slightly-their-deadly-risks-need-to-be-weighed-against-any-benefit-171936

Times Magazine

Can bigger-is-better ‘scaling laws’ keep AI improving forever? History says we can’t be too sure

OpenAI chief executive Sam Altman – perhaps the most prominent face of the artificial intellig...

A backlash against AI imagery in ads may have begun as brands promote ‘human-made’

In a wave of new ads, brands like Heineken, Polaroid and Cadbury have started hating on artifici...

Home batteries now four times the size as new installers enter the market

Australians are investing in larger home battery set ups than ever before with data showing the ...

Q&A with Freya Alexander – the young artist transforming co-working spaces into creative galleries

As the current Artist in Residence at Hub Australia, Freya Alexander is bringing colour and creativi...

This Christmas, Give the Navman Gift That Never Stops Giving – Safety

Protect your loved one’s drives with a Navman Dash Cam.  This Christmas don’t just give – prote...

Yoto now available in Kmart and The Memo, bringing screen-free storytelling to Australian families

Yoto, the kids’ audio platform inspiring creativity and imagination around the world, has launched i...

The Times Features

Here’s what new debt-to-income home loan caps mean for banks and borrowers

For the first time ever, the Australian banking regulator has announced it will impose new debt-...

Why the Mortgage Industry Needs More Women (And What We're Actually Doing About It)

I've been in fintech and the mortgage industry for about a year and a half now. My background is i...

Inflation jumps in October, adding to pressure on government to make budget savings

Annual inflation rose[1] to a 16-month high of 3.8% in October, adding to pressure on the govern...

Transforming Addiction Treatment Marketing Across Australasia & Southeast Asia

In a competitive and highly regulated space like addiction treatment, standing out online is no sm...

Aiper Scuba X1 Robotic Pool Cleaner Review: Powerful Cleaning, Smart Design

If you’re anything like me, the dream is a pool that always looks swimmable without you having to ha...

YepAI Emerges as AI Dark Horse, Launches V3 SuperAgent to Revolutionize E-commerce

November 24, 2025 – YepAI today announced the launch of its V3 SuperAgent, an enhanced AI platf...

What SMEs Should Look For When Choosing a Shared Office in 2026

Small and medium-sized enterprises remain the backbone of Australia’s economy. As of mid-2024, sma...

Anthony Albanese Probably Won’t Lead Labor Into the Next Federal Election — So Who Will?

As Australia edges closer to the next federal election, a quiet but unmistakable shift is rippli...

Top doctors tip into AI medtech capital raise a second time as Aussie start up expands globally

Medow Health AI, an Australian start up developing AI native tools for specialist doctors to  auto...